Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
November 2, 2023
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, everyone, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Fady Malik, who serves as EVP of R&D, will then share updates on aficamten, with a focus on SEQUOIA-HCM and FOREST-HCM; Stuart Kupfer, SVP and Chief Medical Officer, will give further updates on aficamten tied to SEQUOIA-HCM and MAPLE-HCM, and we will also go over our early-stage pipeline, which includes CK-586 and CK-136. Andrew Callos, EVP and Chief Commercial Officer, will talk about commercial readiness efforts for aficamten. Robert Wong, VP and Chief Accounting Officer, will walk through a financial overview of the quarter just ended; and Ching Jaw, SVP and Chief Financial Officer, will cover our financial outlook along with corporate development strategies. Then, to wrap up, Robert Blum will offer closing remarks and go through the key milestones we expect ahead. Please be aware that parts of what we discuss next, including answers we give to questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. You can find more details about the factors that might cause our actual results to differ materially from those in these forward-looking statements in our SEC filings, including our current report on our third quarter 2023 financial results, furnished to the SEC today on Form 8-K. Following this call, we have no obligation to update any forward-looking statements. With that, I'll hand the call over to Robert.
Robert Blum
executiveThanks, Diane, and I appreciate everyone being with us today. I feel good about what we accomplished during Q3, especially our work on aficamten, which is our number one priority, and our focus on carrying out SEQUOIA-HCM and moving its wide-ranging development program forward. Because of how hard and carefully our teams have worked, we're still on schedule to report topline findings from SEQUOIA-HCM in late December. That schedule is certainly tight, but our confidence comes from the excellent coordination and supervision of SEQUOIA-HCM provided by our clinical operations and statistical groups, and like everyone listening, we can't wait to see those topline findings. Fady will say more, but we hold a firm belief that the topline findings from SEQUOIA-HCM will match our lofty hopes on safety as well as efficacy, given the patient population that was enrolled in SEQUOIA-HCM and the distinct characteristics of aficamten. Should SEQUOIA-HCM match what we hope for on efficacy as well as safety, we believe it could help grow the cardiac myosin inhibitor, or CMI, category on both fronts. At the same time, during Q3 we kept growing our specialty cardiology franchise by moving forward the clinical trials already underway in the aficamten development program, along with earlier-stage clinical research, with enrollment now ongoing in both MAPLE-HCM and ACACIA-HCM, and we see multiple catalysts for aficamten coming soon. To complete our specialty cardiology franchise, there's CK-586, a second cardiac myosin inhibitor, and CK-136, a cardiac troponin activator, and Stuart will give an update on those. Our cash position when the quarter closed gives us more than 18 months of cash runway, measured against our 2023 net cash burn guidance. Just as importantly, following our usual approach for financial strength and sensible planning, we're gating spending until the topline results of SEQUOIA-HCM read out, and we're carefully directing what we spend now toward our top priorities, once again centered on aficamten, with a sharp eye on cost efficiencies. Today you'll hear about the progress we kept making in Q3 and what's ahead through year-end, as we get closer to 2024 and, as you heard a few weeks back at our Investor and Analyst Day, Cytokinetics stays laser focused on fulfilling the promise of aficamten and on moving our earlier-stage pipeline ahead, while we build our specialty cardiology franchise for the potential good of patients and shareholders alike. With that, I'll hand the call to Fady.
Fady Malik
executiveThanks, Robert. During Q3, we achieved substantial progress throughout the aficamten development program. Not long ago, we were delighted to share baseline characteristics for patients who had been enrolled in SEQUOIA-HCM, our pivotal Phase III study of aficamten, at the HCM Society Scientific Sessions. Those baseline characteristics fulfilled what we had aimed for regarding the intended trial population, since we had enrolled a worldwide, varied, real-world group of patients who had a considerable reduction in exercise capacity along with a notable symptom burden even while receiving existing standard of care. For those enrolled in SEQUOIA-HCM, the mean peak oxygen uptake, or peak VO2, stood at 18.5 milliliters per kilogram per minute at baseline, equivalent to 56.9% of what would be predicted for their age and sex, which serves as an objective marker of how much their exercise capacity was reduced. Close to one quarter of patients fell into NYHA functional class III, and their average KCCQ score was 74.7, which further reflects a population with a high symptom burden despite being on guideline-directed medical therapies as background treatment. That background medical therapy consisted of beta blockers, calcium channel blockers, and disopyramide, and patients were allowed to get combination background medical therapy. Beta blockers, which are recognized for blunting maximum exercise capacity because they slow heart rate, were given to 61% of patients; we are extremely pleased that our goals were met and that the population we enrolled was the one we intended. As the SEQUOIA-HCM readout gets closer later this year, we have confidence in how complete the data are and that we are surpassing the design assumptions for the trial. Both the amount of missing data and the standard deviation of the primary endpoint fall inside our assumptions, which ought to boost the trial's power to evaluate the change in the primary end point. I am also happy to say that almost every patient has finished dosing, and sites have not reported any patient with an LV ejection fraction below 40%; we look forward eagerly to sharing top line results in late December. We hold strong convictions that SEQUOIA-HCM's results will match our expectations. Those convictions get additional support from the long-term efficacy and safety of aficamten that we are seeing in FOREST-HCM, the open-label extension clinical trial. At our recent Investor and Analyst Day, we presented new longer-term data, with data available for some patients extending beyond two years. Over 200 patients have been enrolled in FOREST-HCM so far, and data from 143 patients with obstructive HCM were available for this analysis. The new FOREST-HCM data demonstrated that no patient experienced a treatment-related LV ejection fraction below 50% during the treatment period — during the titration period — and roughly two-thirds are receiving 15 milligrams or 20 milligrams of aficamten. Throughout the maintenance phase of FOREST-HCM, there have been no instances of LVEF plus with 40%, which would call for treatment interruption, and only three instances of LVEF below 50% that merely required a dose down titration. Out of 579 monitoring echocardiograms that were performed while patients were in the maintenance phase of treatment, 99.5% did not lead to a down titration of dose. In addition, in this reported FOREST-HCM data, we saw that mean resting and LVOT gradients stayed lowered and remained beneath the diagnostic threshold for obstructive HCM following more than two years of treatment. Sustained decreases in cardiac biomarkers were also seen in patients, along with better symptoms. Roughly half of patients were NYHA functional class I or asymptomatic, while 80% of patients got better by one or more functional class. Moreover, 90% of the SCT eligible patients at baseline were no longer SCT eligible when this analysis took place. aficamten has generally been well tolerated, and investigators assessed no treatment-related serious adverse events. In addition, about 30% of patients have lowered doses of background therapy or have stopped it entirely, at the treating physician's discretion and/or because the patient requested it. This backs the rationale for MAPLE-HCM, which Stuart will talk about next. These new FOREST-HCM results are pretty compelling, and we look forward to collecting more longer-term data for aficamten in this open-label extension. Turning briefly back to SEQUOIA-HCM after the top line readout of the results in late December, we expect to hold a meeting with FDA in the first quarter of next year to talk over the top line results, with the aim of potentially submitting a new drug application for aficamten in the second half of 2024. At that initial meeting to review the top line results, we'd expect to start a dialogue about how the safety and efficacy of aficamten seen in REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM would shape the design of a REMS program. We look forward to those interactions, and we'll give further updates next year. Now, I'll pass it to Stuart to go into more detail on additional progress we made for aficamten and to give an update on our earlier-stage clinical pipeline.
Stuart Kupfer
executiveThank you, Fady. In Q3, we kicked off ACACIA-HCM, a pivotal Phase III study of aficamten involving symptomatic nonobstructive HCM patients. Investigator excitement is significant, since a large number of the sites taking part in ACACIA-HCM already have experience using aficamten through REDWOOD-HCM, FOREST-HCM, and SEQUOIA-HCM. Also, as many of you are aware, people living with nonobstructive HCM have few therapeutic choices. The usual standard of care drugs, such as beta-blockers and calcium-channel blockers, deliver limited benefit, so individuals with non-obstructive HCM frequently endure a substantial symptom burden. What we aim to achieve with this trial is to collect evidence regarding aficamten's potential for this key subset of the HCM population, which has no available treatment. During Q3, we additionally kept up patient enrollment in MAPLE-HCM, the Phase III trial assessing whether aficamten as monotherapy could show superiority over metoprolol as monotherapy among obstructive HCM patients; we're happy to share that enrollment is moving forward as anticipated. Should results be positive, MAPLE-HCM ought to back the prospect of aficamten being viewed as a first-line option for obstructive HCM. Turning now to our earlier stage pipeline. As Robert noted, we likewise achieved progress moving both CK-586 and CK-136 forward during the quarter. We have finished the single-dose cohorts among healthy volunteers in the Phase I trial of CK-586, our cardiac myosin inhibitor being developed as a possible treatment for a subgroup of patients who have heart failure with preserved ejection fraction, or HFpEF, with hypercontractility. Our analyses of the single-dose cohorts are now done, and they support moving ahead to the multiple dose part of the study, which we anticipate beginning in this fourth quarter. While the Phase I study continues, we also recently shared new preclinical data on CK-586 at our Investor and Analyst Day, demonstrating better diastolic function and less cardiac fibrosis in an animal model of HFpEF; these findings, together with what was seen with aficamten in non-obstructive HCM, which shares features resembling those of HFpEF with hypercontractility, reinforce the potential advantage of CK-586 for this patient population. Moving on to CK-136, our cardiac troponin activator, we finished the single ascending dose cohorts in the Phase I study among healthy participants. And at this point we're examining that data to guide whether we potentially move forward to the multiple dose cohorts of the Phase I study; with that, I'll hand the call over to Andrew.
Andrew Callos
executiveThanks, Stuart. As we shared during our Investor and Analyst Day, the way we're thinking about being commercially ready in 2023 revolves around grasping the patient journey and the whole experience of living with HCM. So because of that, we've been working to develop a thorough grasp of the HCM market, with the goal of crafting the best possible experience for physicians and patients. Over the quarter, we kept carrying out market research to evaluate possible patient profiles and the market segments that exist in obstructive HCM, and this research has verified the symptomatic patient population that needs disease-modifying treatment with a possible next-in-class CMI. By tying our commercial strategies to this patient-centric way of doing things, we're getting ready to meet a significant unmet customer need, aiming to have a positive effect on patients and shareholders should aficamten get approved. At the same time, our market research is teaching us that physicians express considerable interest in the possible target product profile for aficamten, which shows there's opportunity to capture CRM share among HCM patients who are newly treated, along with the chance to grow the total CMI market. On top of that, we anticipate that CMI penetration among eligible — obstructive HCM patients will be under 20% when aficamten is expected to launch, which means more than 80% of the obstructive HCM eligible patient population will still go without treatment with the CMI; so we're directing our commercial readiness strategies toward those that enable expanded use of CMIs, building on the expected next in-class profile of aficamten coming out of our clinical trials program; we'll also work to create a seamless and patient-friendly CMI experience via a comprehensive patient support program, helping to meet the emotional, financial and educational needs a patient has throughout their journey. Keeping the patient experience in mind, we recently ran a mystery theater program at the HFSA Annual Scientific Meeting, where we led a discussion about the impact of obstructive HCM, which may have a patient on patient quality of life, mental health and well-being, and also about how cardiologists can better grasp and tackle these concerns; this way of elevating the holistic and human-centric view of HCM is connecting with HCTs, and we hope it might help encourage better position patient conversations, and boost awareness of the myriad impact of HCM. Through the end of the year, we intend to keep up our market research and go-to-market planning for aficamten. In 2024, our seasoned team will move its focus to designing and building our commercialization strategies, guided by market research, the results of SEQUOIA-HCM and our deepening market insights. With that, I'll turn the call over to Robert Wong.
Robert Wong
executiveAppreciate that, Andrew. We closed out Q3 holding $554.7 million across cash and investments. In the course of the quarter, the commencement of ACACIA-HCM triggered a $50 million milestone payment to us from Royalty Pharma, which under GAAP gets recorded as a liability on our balance sheet. Also, not long ago, Ji Xing paid us a $2.5 million milestone tied to ACACIA-HCM getting underway. R&D expenses for the third quarter of 2023 rose to $82.5 million, up from $62.7 million during the same period in 2022, largely driven by outlays on our cardiac myosin inhibition programs. G&A expenses came in at $40.1 million for Q3 2023, a decline from $48.2 million in Q3 2022, mainly reflecting reduced spending on outside services. At this point, I'll pass things to Ching, who will walk through our financial outlook and corporate development strategy.
Ching Jaw
executiveAppreciate that, Robert. Like Robert said, we closed out the quarter with roughly $555 million sitting on the balance sheet, and that gives us more than 18 months of cash runway, calculated from our 2023 net cash burn guidance. During the back half of the year, we've trimmed our outlays and we're taking a hard look at which spending priorities matter most going forward, so we can get the strongest possible return on the money we commit. Aficamten is still our number one focus, and as 2024 gets closer, we're staying disciplined with what we spend on getting ready for a possible commercial launch of aficamten. Along those lines, we're building up expenses before we share the top line results of SEQUOIA-HCM. After we have those results, and assuming they come back positive, we'll be in a position to sharpen our assumptions even more and decide where to release funds. As we always do, we intend to give guidance on our 2024 spending when we hold the Q4 earnings call. Regarding our ability to raise capital, let me remind everyone that because of the transaction we did with Royalty Pharma, we can still draw two more loan tranches under our development funding agreement — one of $75 million if we potentially report positive results from SEQUOIA-HCM, and another of 100 million if an NDA submission for aficamten gets accepted in the US. On the corporate development side, we've spent the year running a thorough process, sitting down with a number of possible partners. We've seen a strong level of interest in aficamten, sometimes on its own and sometimes alongside the possibility of including only omecamtiv mecarbil in territories outside North America. That process has confirmed the value proposition behind our go-to-Europe strategies; that being said, we don't anticipate signing a partnering deal before we announce the top-line results from SEQUOIA-HCM, and we'll keep assessing how we obtain and allocate capital, since SEQUOIA-HCM will teach us more about aficamten. At this point, I'll hand the call back over to Robert Blum.
Robert Blum
executiveThank you, Ching. As we get ready to wrap up 2023, our company is nearing a significant turning point; aficamten sits at the forefront of our specialty cardiology franchise, and the topline data from SEQUOIA-HCM could speed up our momentum as we prepare for transitions that would make us a fully integrated biopharmaceutical company in 2024; during 2023, a great deal was set in motion that is now moving us nearer to our aim of delivering new medicines for patients who suffer from diseases involving impaired muscle function. Although aficamten and our earlier stage pipeline remain our priority, in the quarter we filed a formal dispute resolution request with the FDA's Office of New Drugs concerning the CRL, or complete response letter, for omecamtiv mecarbil. What we seek is to challenge the FDA's determination that substantial evidence of effectiveness has not been established to support approval of omecamtiv mecarbil. As I've mentioned previously, at present we have no plans to run another clinical trial of omecamtiv mecarbil, and it's possible we won't be able to resolve the deficiencies identified in the CRL; even so, we continue to have faith in the science behind omecamtiv mecarbil and in the evidence demonstrated that could potentially help patients with advanced or worsening heart failure. Should our appeal to FDA succeed, we would then weigh possible next steps for omecamtiv mecarbil, though and importantly, through the lens of a company whose top priority is aficamten; we are also still pursuing possible approval for omecamtiv mecarbil outside of the US. Turning to Europe, we have submitted our responses to the day 120 questions to the EMA and are now waiting for their feedback. When it comes to China, our partner JI XING filed a request for voluntary withdrawal of the NDA for omecamtiv mecarbil with the Center for Drug evaluation of the National Medical Products Administration of the People's Republic of China, subject to possible resubmission should we receive favorable feedback from EMA or FDA regarding potential drug approval for omecamtiv mecarbil in the EU or US respectively. Moving now to business development, as Ching said, and to be clear, we do not anticipate partnering aficamten ahead of the readout of SEQUOIA-HCM. Our focus stays on that which is within our control and that which matters most for our company and for patients and shareholders, which is advancing Aficamten; even so, it reinforces our corporate strategies to have engaged with potential partners who have shown a high level of interest in Aficamten and ultimately validate our own planning. We believe we are doing right by all of our stakeholders by objectively and critically evaluating our own plants. Consequently, once results from SEQUOIA-HCM read out, we'll be better positioned to execute on our strategies. As we near the close of 2023, we look back on a year marked admittedly by both ups and downs; we have encountered certain setbacks that tested our company's grit and resilience, but we've also achieved great progress. So at this point, we find ourselves in a distinctive spot to achieve success, thanks to a robust specialty cardiology business, which is anchored by our very own extensive late-stage development effort for Aficamten, along with earlier-stage drug prospects that have come out of our research that leads the industry, plus our leadership when it comes to muscle biology and the mechanics of contractility. Beyond that, the ties we have with important stakeholders, together with the capital we can access, make us stand out, and so do our enthusiasm, our commitment to what we're trying to accomplish, and our determination to do the right thing for patients. When I think about 2024, I feel optimistic and excited about what lies ahead. One more thing before I go over the milestones coming up: as we head toward the results and the SEQUOIA top line readout in late December, we intend to begin a quiet period on Monday, December 4. Now, the milestones ahead of us: when it comes to Aficamten, we anticipate sharing top line results from SEQUOIA-HCM in late December, along with ongoing patient enrollment in Maple HCM and Acecia-HCM, and we'll keep moving our go-to-market plans forward for Aficamten. As for omecamtiv mecarbil, we anticipate carrying on with efforts to seek possible approval for it in Europe. And regarding CK-136, we anticipate reviewing data from the single ascending dose cohorts in the Phase I study, which will help determine whether we potentially move ahead into the multiple ascending dose cohorts within that same Phase I study. Then last, for CK-586, we anticipate moving ahead into the multiple ascending dose cohorts in that Phase I study during this quarter, Q4 2023. Operator, that being said, let's go ahead and open the call for questions now, please. Good afternoon, Joe.
Joe Pantginis
analystHey everyone. Good afternoon, and thanks for taking my question. I'm curious about what Fady said regarding the patient populations in SEQUOIA. Specifically, could you give us more detail about the reductions in background therapy and, even more importantly, how those reductions could lead to better quality of life and improved safety for these patients? Then, second, just quickly, is there anything meaningful to say about the cost impacts of the formal dispute with the FDA and the EMA filings for afacamtin? Thanks a lot.
Robert Blum
executiveSure. I'll have Fady respond to your first question, and I'll handle the second.
Fady Malik
executiveAppreciate that, Joe. Now, when it comes to taking patients off background therapy, the study design — which we shared previously at ACC — permits the investigators to pull either beta blockers alone or other background agents, like disopirmide or calcium channel blockers, depending on how well the patient tolerates it. At the same time, they can also raise the afacamtin dose as needed to make up for it. So what we're seeing — I don't have precise percentages for you — is a substantial share, roughly two-thirds in my view, coming off all background therapy. In most instances, they've managed to stop disopirmide, and with beta-blockers too, the withdrawal has gone pretty well. From the patient's perspective, then, this makes their medical treatment simpler. It frees them from some of the bothersome adverse events those drugs cause, and it streamlines their medication routine.
Robert Blum
executiveAs for what you asked next about possible expenses tied to filing that formal dispute resolution, those are actually pretty minor. They involve work done in-house, along with counsel, and there aren't any fresh studies or fresh analyses — nothing amounting to a significant outlay of money.
Joe Pantginis
analystThank you, guys.
Robert Blum
executiveThank you.
Dane Leone
analystHey, how's it going, Robert and team? Yeah, we've been talking quite a bit recently. So honestly, there's just one question I have that keeps surfacing among investors: since the SEQUOIA topline is coming late in December, could you give us any sense of how you expect the team to approach disclosing those topline results? A lot of folks, I think, look back at some of the early REDWOOD disclosures your team put out, around how some of the key primary endpoints were described, and maybe some specifics regarding left ventricular ejection fraction adverse events. But anything you could share about how your team intends to approach this, I think, would really help set expectations. Thank you.
Robert Blum
executiveSure. I'll give it my best shot, though we should acknowledge that without the data in hand, it's tough to be as precise as you'd probably like us to be. Still, our aim is to share all of it, and that ought to hopefully demonstrate our ability to have achieved a next-in-class, potentially best-in-class profile for afacamtin. Whether much of that ends up being quantitative, with p-values, primary and secondary endpoints, safety and adverse effects, will in the end hinge on what we can take into consideration alongside, hopefully, the American College of Cardiology, where we'd hope to present these data, even if that's not until several more months down the road. So our aim will be to communicate as much as we're able, while recognizing we don't want to put at risk any presentation at a proper scientific forum, so we understand what's expected if we're going to have a next-in-class, potentially best-in-class profile. And those are the things foremost on our minds as we consider what we can disclose. Naturally, we have to disclose whatever is deemed material to shareholders.
Dane Leone
analystExcellent. Thank you.
Robert Blum
executiveThank you.
Robert Blum
executiveHello there, Selim, good afternoon.
Salim Syed
analystHey, good afternoon to you as well, Robert. Let me pose something here. I want to piggyback on the SEQUOIA discussion. What I'm hoping is that either you or Fady can help clarify the proper way for us to think about comparing mavacamten against aficamten. For aficamten, there was a 1.4% unit change when it comes to peak VO2, and my recollection is that roughly 6% had an injection fraction below 50%. So I'm wondering whether you could lay out for us the boundaries — the low end and the high end — regarding peak VO2. For instance, does a one point difference at 1.8 represent a point where the two would be considered comparable? Or at what threshold do you begin to sense that efficacy can genuinely be distinguished? And I'd ask the same thing regarding safety: how much separation from mavacamten is necessary before you feel confident that a real difference exists, and what does that imply for our REMS and similar matters? Thanks.
Robert Blum
executiveOf course, Salim. It should come as no shock that I will once more stress that no comparative claims involving mavacamten will be made by us. The study known as SEQUOIA-HCM differs from EXPLORER-HCM, the trial that resulted in mavacamten receiving approval. The only things I can address, and the only things Fady can address, concern aficamten itself, along with our hopes for eventual labelling and positioning. How doctors ultimately view these two prospective medications is what will shape our ambition of growing the category and achieving best-in-class status. Having offered that lengthy qualification, perhaps I'll turn it over to Fady so he can do his utmost to address our expectations regarding aficamten in SEQUOIA-HCM.
Fady Malik
executiveRight. Salim, my sense is that what we'll observe — and what we're hoping to observe — is that these shifts will be sizable enough that the real issue stops being about whether there's a minor gap between one option and the other. When it comes to both of these drugs — well, with mavacamten, we already know it works quite well in patients. Our hope is that aficampten turns out to be just as effective, or perhaps even more so. Judging that sort of thing purely by lining up one individual figure against another doesn't really work, in my view. What you actually need is to examine the full picture of the data spanning every endpoint. And you need to pair that with the safety profile, as we may once again end up seeing in the study. So there isn't a straightforward response to what you're asking, even though I realize you'd like me to give you one.
Salim Syed
analystAll right, that's fine. I had been meaning to pose that one, but I'm grateful for the response. Thanks very much.
Robert Blum
executiveThanks to you as well, Salim.
Robert Blum
executiveHi, Jason.
Analyst
analystGood afternoon. Cameron Rosa here, calling in from Bank of America Securities, sitting in for Jason Zemansky. Nice work on the progress, and I appreciate you taking my question. If I could, I'd like to pose a follow-up regarding EF. Data was recently reported by you from FOREST-HCM OLE in which 3 patients experienced an LVEF production under 50%. In your view, what must be demonstrated when it comes to LVEF productions in SEQUOIA so that regulators feel at ease allowing fewer echos under a possible REMS — do those have to drop beneath EXPLORER 6%, or, given the death in MAPLE EXPLORER, will regulators take a more cautious stance on this class overall, at least at the start?
Robert Blum
executiveSure. Thank you for asking that. I've gone through some of the research your team has put out on this topic, and perhaps I can shed some light on our thinking. Our examination of SEQUOIA-HCM data comes after we already talked with FDA while designing SEQUOIA-HCM about a protocol allowing down titrations in cases where EF drops under 50%, rather than dose interruption or dose termination. The ramifications of down-titration sit comfortably inside what's typical for cardiology group practices in this space. So we'll examine the SEQUOIA-HCM data, once it's on hand, through that same lens — meaning, in my view, the real issue isn't whether it's 3% or 6% or some figure in between. Rather, it's about how this genuinely impacts patients and physicians, and how FDA would likely regard what happens should EF drop. What gives us confidence is that aficamten's half-life permits a fairly swift return to normalcy where EF is concerned, so if EF does decline, the effect may be inconsequential. Given that, a straightforward down titration ought to be acceptable to physicians, free of any concerns or worry. In our view, that could prove quite significant for aficamten's eventual profile. So I wouldn't fixate on the number. Even though, as Fady reported, EF excursions have been quite few, and 99.5% of echos led to no dose adjustment whatsoever — except that these down titrations may happen on occasion — I'd expect that to go a considerable way toward providing, hopefully, should the SEQUOIA data turn out as we saw in FOREST, a profile that gets judged next in class. Fady, is there anything you'd like to add?
Fady Malik
executiveI'd also point out that cardiologists happen to be very skilled when it comes to handling medications requiring monitoring. Take, for example, heart failure treatments such as mineralocorticoid receptor antagonists — for a long time these agents have been recognized as capable of driving potassium upward, at times to levels that threaten life. When you look at the label for something like eplerenone, that applies to 1% to 4% of patients who take such medicines. So it's not — monitoring-dependent drugs are nothing new to a cardiologist. Therefore, in the end I don't believe that, once someone grows familiar with a class, it's at all shocking to find that monitoring starts shifting as time passes and turns into a routine element of practice. Thus, as Robert put it, what has been observed so far with aficamten, combined with growing comfort regarding the class, would ideally yield an approach that patients and physicians alike find sensible to carry out while keeping patient safety intact.
Cameron Bozdog
analystAppreciate the color. Thank you.
Fady Malik
executiveThank you.
Robert Blum
executiveHello there, Serge.
Serge Belanger
analystHi, Robert. I want to follow up on something asked earlier about the information we anticipate coming out in late December. Historically, ACC has been quite tight-lipped about what may be revealed before a late-breaking clinical trial presentation at their meeting; sometimes all we learned was whether a primary endpoint was hit; so I'm just wondering, are you sure you'll be permitted to share additional data beyond that, covering both the efficacy and the safety aspects of the trial? Thanks.
Robert Blum
executiveThanks. Once more, without the data in hand, it's hard to give as clear an answer as you'd ideally like. That said, yes, I'm sure. My belief is that we can say what needs to be said, satisfying our goal of disclosing what's considered material for shareholders' benefit while also making a proper presentation possible at the ACC when that time arrives. This isn't new territory for us. It hasn't been for others either. And I believe this is achievable. Next?
Robert Blum
executiveGood afternoon.
Analyst
analystHello, and good afternoon. Many thanks for allowing us to ask a question. This is Fatima speaking for Ash Verma of UBS. We have just a couple of quick items. From the baseline characteristics, we can see that beta blocker usage in your trial is low, and that fact could help isolate the effect size for aficamten. However, given that in the actual clinical setting beta blocker use is quite common, the real-world effect size for aficamten might turn out smaller than whatever gets demonstrated in SEQUOIA. Also, quickly, a second item: we would like to hear your perspective regarding how LVOT reduction relates to peak VO2. Certain studies, such as one from KEMZYO, indicate a correlation, whereas other research involving beta blockers indicates no correlation at all. So when it comes to aficamten, how do you view the possibility of a correlation, or the correlation itself, between those two endpoints?
Robert Blum
executiveCertainly. Let me begin, and afterward I'll have Fady address the questions you raised. The study we designed and ran, SEQUOIA-HCM, we consider highly representative of the population that aficamten, we hope, will eventually be approved to treat. Thus it isn't an artificial construct. It isn't a manufactured population. In truth, it is real world. And because of that, we took considerable care to make sure this trial would let physicians, once data becomes available, apply these findings within their own practices. With that said, I'll hand things over to Fady.
Fady Malik
executiveRight. I want to bring back to mind what I mentioned — 61% of the majority of patients are on beta blockers. That aligns with what you'd observe in actual practice. Beyond that, consider calcium channel blocker usage, plus the permitted combination treatment involving calcium channel blockers alongside beta blockers, or beta blockers alongside dicoparamide. My contention is that SEQUOIA-HCM delivers a highly pertinent real-world picture regarding aficamten's efficacy once those data are available. Thus, I believe the baseline characteristics essentially settle that question; they demonstrated a substantial level of background medical therapy being utilized. On the second point, as we highlighted, background therapy might not be ideal for these patients. In the end, certain of these background therapies could be restraining them, with beta blockers serving as one illustration. A reason you observe weaker correlations between LVOT gradient reduction and peak VO2 stems from beta blockers breaking that correlation, since without the capacity to raise your heart rate while exercising, even after the gradient is resolved, you can boost exercise performance because you're able to raise your heart rate. Consequently, it's unfortunately more intricate than a tidy scientific trial in which you alter one variable and gauge a different variable; yet broadly speaking a solid correlation exists, and lowering the gradient has consistently been the aim of both medical and surgical treatment. And clearly there's precedent within the class that reducing the gradient enhances PVO2.
Fatima Amanat
analystGreat. Thanks for taking the question.
Robert Blum
executiveThank you.
Robert Blum
executiveHey, Jason.
Jason Butler
analystHi. I appreciate you taking my question. Hello, Robert. I was just curious whether you might share, from the standpoint of commercial planning, how input from the FDA — presuming positive results from SEQUOIA and that you sit down with the agency in 1Q 2024 — would affect your commercial strategy and the scenarios you're considering, in a case where the REMS ends up comparable to mavacamten or is less onerous than mavacamten? Thanks.
Robert Blum
executiveLet me just check that I've got your question right. Would you mind repeating the opening portion?
Jason Butler
analystYeah. So when the FDA gives you feedback regarding what a REMS program could potentially look like, in what ways would that shape your commercial planning under scenarios where the REMS resembled mavacamten, or was less of a burden than mavacamten?
Robert Blum
executiveOkay. No, I follow you. Thanks. I'll turn some of this over to Andrew, but please keep in mind that without the data at this moment, these are hypothetical situations we've already considered in market research; and after we obtain the data, we'll be in a position to conduct more refined market research, and in the end, should we propose a REMS, that is something that will be accomplished via interactions between the sponsor and FDA; so all of this remains subject to a substantial amount of uncertainty until we have the data upon which it's based. That said, we do hold certain expectations, having seen REDWOOD data, having seen FOREST data; and having grasped what underlies the REMS for the other cardiac myosin inhibitor, we have a perspective on what could ultimately make a lesser REMS possible, though that remains fairly speculative, as you might imagine, at this point in time. Andrew, could you address how you've come at this from the market research angle?
Andrew Callos
executiveOkay, so I think there are a couple of key points to grasp here. First, early on in the review, we likely won't get much detail about what a REMS program will actually end up looking like. We did submit a proposal to the FDA on that. But when it comes to our patient support services, regardless of how the REMS turns out, some components of patient support will definitely be provided. For example, we know we'll provide patient assistance and co-pay support; we'll examine echo reimbursement. We'll assist with benefits verification and education about disease states. So certain minimum things are certain, and those we will do. Depending on how complex the REMS is, there are additional things we'll also do. When we plan, our assumption is that we're dealing with a complex REMS containing every element, and it's much simpler for us to reduce or scale back from that once the REMS program becomes clear, because when it does become clear, it's a negotiation — you're negotiating a label near the end — and we wouldn't have sufficient time to respond; so I hope that gives you a feel for our thinking on this.
Robert Blum
executiveOne more thing I want to say. When you go through the summary basis of approval, you can pick up quite a bit regarding what the FDA aimed to achieve when it established the REMS program currently in place; and clearly, because of that earlier understanding, we'll be positioned to recognize what we must take from the FOREST and SEQUOIA evidence so that we can hopefully make possible something that looks different. In the end, though, that's a matter to be addressed later on, once a new drug application has been accepted and reviewed.
Jason Butler
analystOkay. Thank you.
Robert Blum
executiveThank you.
Robert Blum
executiveMorning.
Srikripa Devarakonda
analystMorning, Robert, and hello to everyone on the team. I appreciate you fitting my question in. I'm genuinely eager to see the data, which should arrive in roughly a couple of months — hopefully sooner than that. My question concerns the MAPLE trial. You mentioned that you're enrolling patients who haven't had any prior therapy, along with those who had been receiving background therapy but then came off it. Could you remind me whether there's any limit on how long such patients may have been symptomatic while on therapy and on standard of care? And how did that factor into the statistical powering of the study?
Robert Blum
executiveThose are excellent questions. Let me hand it over to Fady.
Fady Malik
executiveSince Stuart brought up MAPLE during his portion, I'll hand it over to him for the response. Broadly speaking, though, there was no restriction on how long someone had been taking beta blockers—provided they were able to come off them, they qualified under particular classes. As for how long that period was, I'd rather let Stuart go into more detail.
Stuart Kupfer
executiveYes, I appreciate that question. What we aimed to do here was assess aficamten when used in the first-line setting, or as a possible standalone therapy for individuals who'd already undergone standard of care treatment for, say, several years. So we essentially divided these patients into two categories: one group that had either never been exposed to beta blockers or had stopped receiving beta blocker therapy, or had only taken a beta blocker briefly, and another group that had been on beta blockers or standard of care beyond a year. That, broadly speaking, is the segmentation and the approach behind looking at aficamten monotherapy in the first-line setting versus, once again, potentially a better choice compared with standard of care when given as monotherapy to patients who'd remained on standard of care for a prolonged period. Thus the trial is built, naturally, to test whether aficamten monotherapy might demonstrate superiority over beta-blocker monotherapy within either of those patient subgroups.
Srikripa Devarakonda
analystGot it. Thank you.
Robert Blum
executiveThank you.
Stuart Kupfer
executiveThank you.
Robert Blum
executiveHi, Jeff.
Analyst
analystHello, and good afternoon. Catherine here, filling in for Jeff. Many thanks for taking my question. Earlier, you said that doctors had shown interest and enthusiasm regarding aficamten. We'd like to ask you—whether based on your reader so far or whatever feedback has come your way—which elements of the aficamten profile do physicians perhaps find the most compelling?
Robert Blum
executiveAndrew, could I ask you to answer that, please?
Andrew Callos
executiveAlright, so according to the market research we conducted, when an aspirational profile was shown to physicians, what came up most often as the things they were enthusiastic about were keeping LVEF function preserved—clearly that's the safety piece—a shift in New York Heart class or an improvement, say moving from a three down to a two, or from a three down to a one, or a two down to a one, as an illustration, plus a change in KCCQ and the limited DDIs that truly don't require monitoring when it comes to dosing. Those are the items they brought up that would most strongly push their preference toward aficamten.
Analyst
analystOkay. Thank you so much.
Robert Blum
executiveThank you.
Robert Blum
executiveAfternoon, Yasmeen.
Yasmeen Rahimi
analystHey, Robert. I really appreciate everything you laid out. So I suppose, with data anticipated in late December, and with your company starting a quiet period — I believe on December 4 — could you perhaps clarify what "late December" actually means on your end? And then second, maybe you could say something about how the data has been cleaned as you've been gathering it? Or does cleaning only begin once things are locked out in early December? Thanks. I'd be grateful if you could answer that for me.
Robert Blum
executiveOf course. I'm hoping this helps, though please keep in mind, as Fady told you, that although almost every patient has finished the maintenance phase, a few have not, and there remain further visits that still have to happen, and data collection has to follow those visits before we can lock the database. So even though this project is in its very late innings, it isn't finished yet, which means we cannot give you the precision you might want when you ask what we mean by late December. What we mean is that it will happen in December — were our expectation early December, we'd have told you that. Late December most likely means, as you can picture, several weeks into the month, and ultimately how quickly we achieve database lock and enable analysis will determine it. It's common for a study such as this one to require 4 to 6 weeks or more between database lock and producing the tables, listings, and figures needed to extract top-line results. We intend to move more quickly than that, as fast as possible, depending on what data still need to be gathered. As of right now, we feel quite good about our position regarding data collection, enabling database lock, and analysis. I hope that answers your question.
Yasmeen Rahimi
analystThanks, Robert.
Robert Blum
executiveHi, Charles.
Charles Duncan
analystHey, Robert. You and the team deserve congratulations for how far things have come. We appreciate you fielding our question. There are a couple I'll keep brief. Plenty of excellent questions have come in about SEQUOIA. Still, what I wanted to raise concerns the baseline data, specifically around particular geographies and how they interact. When you consider every patient coming from China as opposed to Europe or Israel, I'm curious whether you see any differences — phenotypic, or maybe behavioral — that in your view could affect how results from China carry over relative to Israel or Europe when it comes to exercise capacity. Thank you.
Robert Blum
executiveThat's a fair question. Let me say that I personally have been in discussions with our colleagues to figure out what we could achieve to make this a genuinely international registrational study, what lessons prior studies offer, and what our current knowledge is. So I'll turn it over to Fady to address the specifics of what you asked.
Fady Malik
executiveHey Charles. When it comes to how someone performs during exercise, I'd say you're looking at an athlete. Take our Olympic-caliber athletes — they hail from every corner of the globe, and you can witness that level of performance, extremely high, among all those groups. So in the same way, I believe studies such as this one give us a chance to observe gains in exercise performance right across the spectrum. I'm happy to say I genuinely trust the quality of the data we've gotten from every one of those regions. We've had experience, in GALACTIC for example, with how patients respond to omecamtiv mecarbil, across all those regions. And the response to cancer was pretty robust, especially in China, as a matter of fact; so right now I don't have any worries when it comes to variability between regions. Naturally, we'll find out once the data come out.
Robert Blum
executiveCharles, just to add on, if what you're asking relates at all to whether there's extra risk because we're enrolling in a number of those regions — I hope you can take some comfort from this: as Fady mentioned, we feel quite good about how sound the data is, the fact that nothing is missing, the standard deviation, and those elements that in the end bear on the statistics. So those are items we keep tracking, and we're quite happy with where we stand.
Charles Duncan
analystYes. That covers what we needed on both fronts — for the individual patient and for the trial site. One final thing from me. Could you sketch this out, Robert, if you're willing? As you picture the goal of turning into a cardiovascular company focused on specialists with rapid growth, which comparable businesses do you point to as the benchmarks that would truly show success across the coming 2 years?
Robert Blum
executiveIn biopharma right now, I honestly don't see a true comparable — a company centered on cardiovascular specialties. Specialty players clearly do exist in other therapeutic fields, such as CNS, for example. What guides us instead, as we expand our pipeline and pursue corporate development, is a focus on opportunities aimed at concentrated customer segments. Those would come with leverage on both pricing and payers, and need only a modest sales and marketing footprint to achieve a high-yield, high-return investment approach; and in our view, the earlier cardiology firms in biopharma lack such advantages, which they'd need to compete effectively. We believe those markets and programs do exist where our science aimed at cardiac muscle supports a fresh business model within biopharma — one where we are confident certain elements translate into maximizing shareholder value; so I hope that addresses what you asked.
Charles Duncan
analystYeah, that answers it. You've studied this sector's past closely, so I'm grateful you shared your views. Thanks.
Robert Blum
executiveThanks.
Robert Blum
executiveAfternoon, everyone.
Roanna Ruiz
analystAfternoon, and thank you. Let me start with something brief. I'd like to hear more about what the 99.5% of monitoring echoes in the FOREST data that required no dose reductions actually mean clinically. And how does that stack up against what doctors observe right now in real-world practice with mavacamten?
Robert Blum
executiveWe'll take that question, though I trust you'll appreciate that we won't offer any comparison involving mavacamten. Fady, would you mind handling it?
Fady Malik
executiveAbsolutely. I believe the motive behind raising that idea — and yes, I do know the motive — was that when we talked about how many echoes there are, and how many of them don't call for a management change, we wanted to convey a sense of what monitoring actually costs you. Suppose you run a test to keep an eye on something, and a meaningful result turns up in fewer than 0.5% of the measurements you perform. Then you owe it to yourself to ask whether your resources are being allocated sensibly and efficiently, and whether other approaches might let you allocate those resources while preserving an equivalent level of safety, yet without weighing the system down nearly so much. So I'd say it falls to us to grasp what drives those extremely rare occurrences, to figure out how to foresee them, and to get rid of the 99% of tests that carry no clinical impact while draining the system heavily in resources, time, and money. That, in the end, is why we included those remarks in our presentation.
Roanna Ruiz
analystGot it. Thanks.
Robert Blum
executiveThank you.
Robert Blum
executiveHello, Justin.
Justin Kim
analystHello, Robert. Good evening to everybody. Apologies, I might have come in somewhat late, though I simply have one brief item regarding, I suppose, the SEQUOIA trial and the enrollment of individuals resistant to SRT. Only because, I guess, the young women data was shared a few weeks ago, I'm wondering whether that data would resemble what we observed in EXPLORER? And is there anything else you can share?
Robert Blum
executiveSo I believe I simply want to confirm we're choosing the correct terminology. I'm not certain that resistant to SRT is the proper phrase. What we were highlighting was those individuals who qualified for SRT before treatment as opposed to after treatment. But perhaps Fady could address that.
Fady Malik
executiveRight, exactly. Those individuals qualify for SRT, meaning their New York Heart Association class is at least three and their gradient stands at 50 or higher. So in FOREST, a couple of weeks back, we took another look at what share of those people stayed eligible for SRT once aficamten therapy began, and just about 10% of them satisfied those requirements following treatment, compared with those who had satisfied them when treatment started. So we don't really capture patients who are refractory to SRT. They simply satisfy the requirements for SRT.
Justin Kim
analystAlright. Perhaps this is only a point of clarification. My understanding is that some patients still had residual gradients after undergoing surgery. I'm simply asking whether those individuals are part of the study, since it has been demonstrated that they do gain a benefit.
Robert Blum
executiveCorrect. No; and for SEQUOIA specifically, individuals who received septal reduction therapy are not allowed to enroll in this trial.
Justin Kim
analystAll right. That's great. And then, maybe to transition from that, regarding the FOREST presentation, is there a kind of natural timeline for the HCM cohort, and when could we potentially observe some additional long-term treatment in that group?
Robert Blum
executiveNow, as far as FOREST goes. Yes. I mean, what we'd like to have happen is for the NCM cohort to get a bit older, so that we end up with roughly at minimum 6 months up to 1 year of follow-up prior to reporting those data. So most likely, you'll see them during 2024.
Justin Kim
analystAlright. We're going to be expecting that ICC or ACC.
Robert Blum
executiveThanks.
Robert Blum
executiveAppreciate it, operator, and a big thank you to all of you for being with us on today's call. There was quite a bit of material discussed, so rather than attempt to pull it together or recap it, I'll just say that we're eager for the SEQUOIA-HCM findings and to share them as a late-breaking presentation later this quarter, in late December; we're grateful for the ongoing backing and the interest you've shown in Cytokinetics. And operator, at this point we're ready to wrap up the call.
Operator
operatorThanks for joining us, and that brings today's conference call to a close. We appreciate everyone taking part. At this point, you're free to disconnect. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.